Please login to the form below

Not currently logged in
Email:
Password:

head and neck cancer

This page shows the latest head and neck cancer news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from ... The first commercial use of this type of

Latest news

  • Daiichi gets breakthrough status for pre-NDA leukaemia drug Daiichi gets breakthrough status for pre-NDA leukaemia drug

    Patritumab is still in mid-stage testing for head and neck cancer. ... Arnaud Lesegretain, Daiichi Sankyo’s vice president, oncology R&D, and head of its AML franchise, said: “There have been limited advances over the past several decades for the

  • Nanobiotix signs €40m deal with the EIB Nanobiotix signs €40m deal with the EIB

    The extra funding will go towards trials of NBTXR3 in the head and neck cancer indication. ... Nanoparticle based cancer treatment research funding is one example of how serious we are in fighting cancer, with the significant support from the EIB to

  • BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

    BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace. Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer. ... Enrolment has been suspended in trials of BMS-986205 in non-small cell lung cancer and head and neck

  • BMS gets OK for monthly Opdivo dosing BMS gets OK for monthly Opdivo dosing

    cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The new monthly injection can be used in a range of

  • AZ bags key lung cancer approval for Imfinzi AZ bags key lung cancer approval for Imfinzi

    Before now Imfinzi was only approved for bladder cancer - where it has to compete head-to-head with other checkpoint inhibitors including Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck ... AZ is also expecting read-outs from The KESTREL and EAGLE

More from news
Approximately 6 fully matching, plus 95 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    sexually transmitted human papilloma virus (HPV), including strains that lead to cervical cancer. ... For example, the remarkable silence around the fact that some strains of HPV can also cause penile cancer, anal cancer, and cancer of the head and neck

  • Pharma deals in August 2015 Pharma deals in August 2015

    virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐ 3112 vaccine in P1/2 for

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... and neck cancer.

  • VentiRx appoints James Kyle Bryan as chief medical officer VentiRx appoints James Kyle Bryan as chief medical officer

    During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology. ... This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... Rubbing salt into BMS’ s wounds, Merck's  Keytruda snagged

  • ASCO 2015: What you missed in Chicago

    Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics